Alphatec's second quarter is the moment the spine company's strategic bet stopped being "high-growth, deeply unprofitable" and started looking like "a normal medtech business that happens to be growing 20%." Total revenue of $213.5 million rose 15% year over year; surgical revenue of $196 million rose 17% on 20% case-volume growth, with 24% more net new surgeon users. Adjusted EBITDA of $36.0 million landed at a 16.8% margin, up 420 basis points from a year ago. The headline GAAP net loss of $25.8 million shrank 37% despite an $11.9 million loss on debt extinguishment from a May refinancing. The same quarter, the company refinanced a year-old convertible and a senior term loan into a $175 million JP Morgan term loan and a $125 million JPM revolver, paid down the prior facilities, and ended the quarter with $119 million of cash, $7.5 million more than the year-ago quarter. Trailing-twelve-month free cash flow turned positive at $2.6 million. Full-year guidance is reaffirmed for revenue at roughly $882 million but raised for adjusted EBITDA from $134 million to $140 million, a $6 million upward revision on the back of 420 basis points of margin expansion in a single quarter. The setup is unusual: a sub-$10 stock, 58% off its 52-week high, with a 20% volume growth print and a margin profile that just crossed 16%.
The thesis is procedural, not financial. ATEC sells a single integrated spine-surgery workflow: an imaging system (the EOS Insight platform), an intraoperative guidance system (the Valence system, released late 2025), and a constantly refreshed set of surgical implants. The argument the company is making to surgeons is that better information before, during, and after the operation produces better outcomes - and that the entire system, used together, beats point products from incumbents Medtronic, Stryker, and Globus. The proof point this quarter is volume: 20% case-volume growth, with 24% more surgeons using the system for the first time. Adjusted gross margin of 72.5%, up 260 basis points from a year ago, is the gross-margin evidence that pricing power is real and that the surgical instruments - depreciation-heavy but reusable - are doing their job. Adjusted EBITDA margin of 16.8% in Q2, the first 17-handle quarter in company history, is the bottom-line evidence that the operating model is breaking even at scale. The bear case is that Q2 benefitted from a 24% surge in new users, and the question is whether conversion holds as the surgeon base widens. The bull case is that the Q2 print is the first full quarter of the Valence rollout, that EOS Insight adoption is still ramping, and that $11.9 million of debt extinguishment in the quarter was the clean-up cost of switching into a $300 million senior facility that funds a $140 million adjusted EBITDA run-rate.
At a reference price of $9.75 (August 13, 2026 close), ATEC trades at $1.5 billion market cap, $2.0 billion enterprise value, 2.4x trailing-twelve-month revenue, and 14.2x the midpoint of the raised full-year adjusted EBITDA guide. The single number the market is wrong about is the duration of the 20% case-volume growth. If the surgeon adoption rate decelerates to a normal meddev 8–10% as the new-user base widens, the 14.2x adjusted EBITDA multiple is full. If 15–20% volume growth holds through 2027, the multiple is a discount to where Globus Medical and Stryker spine trade, and the re-rating to 18–20x adjusted EBITDA is the move. The five tests at the bottom of this report set the dates on which that question answers.